iRadimed Corporation (NASDAQ:IRMD – Get Free Report) announced a quarterly dividend on Friday, October 30th. Investors of record on Friday, November 13th will be given a dividend of $0.20 per share by the medical equipment provider on Friday, November 27th. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, November 13th.
iRadimed has a payout ratio of 40.2% meaning its dividend is sufficiently covered by earnings.
iRadimed Stock Performance
IRMD stock opened at $86.24 on Wednesday. The firm has a 50 day simple moving average of $85.33 and a 200 day simple moving average of $92.08. iRadimed has a 52 week low of $76.35 and a 52 week high of $107.90. The stock has a market cap of $1.10 billion, a P/E ratio of 46.18 and a beta of 0.91.
iRadimed (NASDAQ:IRMD – Get Free Report) last released its quarterly earnings data on Friday, October 30th. The medical equipment provider reported $0.55 earnings per share for the quarter, meeting the consensus estimate of $0.55. iRadimed had a net margin of 26.85% and a return on equity of 23.90%. The firm had revenue of $24.20 million for the quarter, compared to analyst estimates of $23.47 million. Sell-side analysts predict that iRadimed will post 1.92 EPS for the current year.
iRadimed Company Profile
iRadimed Corporation develops, manufactures and markets medical devices designed for use in magnetic resonance imaging (MRI) environments. Its products include MRI-compatible patient monitoring systems and intravenous infusion pumps, along with related accessories. The company’s monitoring systems help clinicians track patients during MRI procedures, while its infusion pumps deliver fluids and medications in the MRI suite. iRadimed’s equipment is designed to operate in the presence of MRI magnets, where conventional medical devices may not be suitable.
Recommended Stories
- Five stocks we like better than iRadimed
- 3 Stocks Wall Street Likes More Than the Market Does
- Anthropic’s Trillion-Dollar IPO Could Give Cloud Giants a Double Win
- The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
- 3 Insider Selling Stories; 3 Different Signals for Investors
Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.
